Skip to content

Istvan Bitter

4 papers in the library · 993 citations · publishing 2019-2026

Papers

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression

JAMA Psychiatry June 5, 2019 Ella J. Daly, Madhukar H. Trivedi, Adam Janik et al. 766 citations

For adults with treatment-resistant depression who achieved stable remission or response after 16 weeks of esketamine nasal spray plus an oral antidepressant, continuing esketamine plus the antidepressant delayed relapse significantly more than switching to placebo plus the antidepressant. Among those in stable remission, 26.7% relapsed on esketamine versus 45.3% on placebo, a 51% reduction in relapse risk. Among stable responders, 25.8% relapsed on esketamine versus 57.6% on placebo, a 70% reduction. Common side effects of esketamine included transient taste disturbance, vertigo, dissociation, drowsiness, and dizziness.

DOI: 10.1001/jamapsychiatry.2019.1189 Full text

Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression

New England Journal of Medicine October 4, 2023 Andreas Reif, Istvan Bitter, Jozefien Buyze et al. 197 citations

In treatment-resistant depression, esketamine nasal spray combined with an SSRI or SNRI led to remission in 27.1% of patients at week 8, compared to 17.6% for extended-release quetiapine plus an SSRI or SNRI. Over 32 weeks, 21.7% of patients on esketamine had no relapse after remission versus 14.1% on quetiapine. The open-label, single-blind, randomized trial included 676 patients. Adverse events matched known safety profiles. Esketamine was superior to quetiapine for achieving remission and preventing relapse.

DOI: 10.1056/nejmoa2304145 Treatment-resistant depression Major depressive disorder Nasal spray Internal medicine +11

Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology August 1, 2024 Roger S McIntyre, Istvan Bitter, Jozefien Buyze et al. 30 citations

In the ESCAPE-TRD trial, esketamine nasal spray caused treatment-emergent adverse events more often than quetiapine extended release (91.9% versus 78.0%), but these events were typically mild or moderate and transient: 92.0% resolved the same day, and only 4.2% of patients discontinued esketamine due to adverse events compared with 11.0% for quetiapine. The median proportion of days with adverse events was lower with esketamine (11.9% versus 21.3%). Along with greater efficacy, esketamine's tolerability profile supports its use for treatment-resistant depression.

DOI: 10.1016/j.euroneuro.2024.05.009 Full text Major depressive disorder Treatment-resistant depression Drug tolerability Quetiapine +5